Izba
Loading...Izba Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
IZBA (travoprost ophthalmic solution) 0.003% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
History
There is currently no drug history available for this drug.
Other Information
Travoprost is a synthetic prostaglandin F2α analog. Its chemical name is [1R-[1α (Z),2ß (1E,3R*),3α ,5 α]]-7-[3,5-Dihydroxy-2-[3- hydroxy-4-[3-(trifluoromethyl) phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethylester. It has a molecular formula of C26H35F3O6 and a molecular weight of 500.55. The chemical structure of travoprost is:
Travoprost is a clear, colorless to slightly yellow oil that is very soluble in acetonitrile, methanol, octanol, and chloroform. It is practically insoluble in water.
IZBA (travoprost ophthalmic solution) 0.003% is supplied as sterile, isotonic, buffered aqueous solution of travoprost with a pH of approximately 6.8 and an osmolality of approximately 290 mOsmol/kg.
IZBA contains Active: travoprost 0.03 mg/mL; Preservative: POLYQUAD* (polyquaternium-1) 0.01mg/mL; Inactives: polyoxyethylene hydrogenated castor oil 40, propylene glycol, boric acid, mannitol, sodium chloride, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water, USP.
Sources
Izba Manufacturers
-
Alcon Laboratories, Inc.
![Izba (Travoprost) Solution [Alcon Laboratories, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Izba | Alcon Laboratories, Inc.
The recommended dosage is one drop in the affected eye(s) once daily in the evening. IZBA (travoprost ophthalmic solution) 0.003% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.
Reduction of the intraocular pressure starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.
IZBA may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Login To Your Free Account